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Introduction 
Atypical carcinoids of the lung are rare neuro- 
endocrine tumours, which are, according to their 
histologic characteristics, classified between typical 
carcinoid and small cell lung carcinoma. We describe 
three patients in whom, within 2 months, atypical 
carcinoid of the lung was diagnosed, and a fourth 
patient whose initial diagnosis of small cell lung 
carcinoma had to be revised after 5 yr. Probably the 
incidence of these tumours is underestimated, as their 
histologic differentiation from typical carcinoid and 
small cell carcinoma can be difficult. 
Case Reports 
CASE HISTORY I 
A 57-year-old woman was admitted in July 1992 
because of dyspnoea and a productive cough. There 
was a 20-pack-yr history of cigarette smoking, until 
1988. Physical examination only disclosed rhonchi at 
the right lung base, blood tests showed slight inflam- 
mation. Neurone specific enolase (NSE) and urinary 
5-hydroxyindole-acetic acid were normal. On chest 
X-ray, atelectasis of the middle lobe was seen, CT 
scan revealed a tumour in the intermediate bronchus, 
with hilar lymphadenopathy and air trapping (Plate 
1). Bronchoscopy showed a polypoid, fragile, endo- 
bronchial turnout-, biopsy of which revealed atypical 
carcinoid (Plate 2). No metastases were detected. 
Echocardiography was normal. Right pneumonec- 
tomy was performed, disclosing invasion of medias- 
tinal fat tissue, and absence of node involvement 
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(pT3NOMO). Until now, there are no signs of 
metastasis or local progression of disease. 
CASE HISTORY 2 
In April 1992, on chest X-ray of a 48-year-old 
woman, a nodule was seen in the right lower lobe. 
The patient was an asymptomatic non-smoker and 
physical examination only showed crackles at the 
right lung base. Blood tests were normal, including 
NSE. CT scan confirmed the nodule in the right 
lower lobe, accompanied by enlarged mediastinal 
lymph nodes. Bronchoscopy was normal, and staging 
disclosed no distant metastases. Transthoracic needle 
aspiration biopsy showed small cell carcinoma. As 
treatment with carboplatin-etoposide for 2 months 
turned out to be unsuccessful, and as this might be a 
case of ‘very limited’ small cell lung carcinoma, 
resection was considered. Mediastinoscopy however 
proved ipsilateral lymph node involvement by atypi- 
cal carcinoid, and restaging showed a scalp metasta- 
sis and a left parietal brain metastasis (proved by 
stereotactic biopsy) (cT2N2Ml). Echocardiography 
was normal. The patient was treated with 
u-interferon, 3 x 5.106E week - ‘. After 2 months, for 
progressive paresis of the right leg, the brain metasta- 
sis was resected and pancranial radiotherapy was 
started. With interferon therapy, the metastases were 
stable but the lung nodule remained slowly progres- 
sive and became symptomatic, so in October 1993 a 
right lower lobectomy was performed. Immediate 
postoperative recovery was uneventful. One year 
later, the patient died of recurrent brain metastases. 
CASE HISTORY 3 
A 61-year-old man who smoked 40 cigarettes per 
day (60-pack-yr) presented in July 1992 with a 
chronic cough and weight loss. On physical examina- 
tion breath sounds were diminished. Blood tests were 
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Plate I Chest CT scan, showing a tumour in the intermediate bronchus (arrow), hilar lymphadenopathy and air I 
(case 1). 
trapping 
Plate 2 Small group of abnormal epithelial cells, with variable nuclear size and shape, and a mitosis (arrow): 
car& noid (case 1). (Hematoxylin and eosin, 350 x ). 
atypical 
nom nal, including NSE. Chest X-ray and CT scan occluded by a tumour, biopsy of which showe :d small 
shov ved a nodule in the right upper lobe, and emphy- cell carcinoma (Plate 3). As there were no distant 
semi itous destruction of the lung parenchyma. On metastases (cTlNOMO), lobectomy was perj ronned; 
bron lchoscopy the right upper lobe bronchus was histologic examination of the resected tissue r evealed 
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Plate 3 Biopsy of a nodule, on which small-cell carcinoma was diagnosed: a group of abnormal cells with enlarged, 
hyperchromatic nuclei with polymorphism. The cytoplasm is very scanty. On one side crush artefacts can be seen (arrow) 
(case 3). On examination of the resected nodule, it turned out to be an atypical carcinoid. (Hematozylin and eosin, 670 x ). 
atypical carcinoid. A few weeks postoperatively, gait 
disturbances, a right Horner syndrome and left 
trigeminal neuralgia appeared. CT scan confirmed 
the presence of multiple brain metastases. Pancranial 
radiotherapy was started, followed by oral etoposide. 
The patient died 13 months after the initial diagnosis, 
of progressive cerebral metastases. 
CASE HISTORY 4 
In 1988, chest X-ray and CT scan of a 56-yr-old 
man showed a solitary nodule in the left upper lobe. 
There was a 35-pack-yr history of cigarette smoking, 
and for about 2 yr he had chest pain, increasing 
exertional dyspnoea and unproductive cough. Physi- 
cal examination only showed an irregular pulse 
(which proved to be due to an atria1 fibrillation on 
ECG), and blood tests, including NSE, were normal 
except for slightly increased alkaline phosphatase 
(bone fraction). Bronchoscopy showed no tumour, 
and there were no metastases. Lobectomy was per- 
formed, and histologically small cell carcinoma was 
diagnosed (pT2NOMO). Three cycles of adjuvant 
chemotherapy were administered (cyclophospha- 
mide, doxorubicine, etoposide). The patient remains 
disease-free until now. This long survival raised 
doubts about the initial diagnosis, and indeed, after 
revision of the histologic sections, the diagnosis was 
changed into atypical carcinoid (Plate 4). 
Discussion 
Neuroendocrine tumours arise from mucosal 
APUD (amine precursor uptake and decarboxyla- 
tion) cells. They contain neurosecretory granules, and 
are subdivided in typical carcinoid, atypical carcinoid 
(or well-differentiated neuroendocrine carcinoma) 
and small-cell neuroendocrine carcinoma (1,2). Some 
authors distinguish a fourth group: the large-cell 
neuroendocrine carcinoma (3). Neuroendocrine 
tumours represent a spectrum of malignancy and 
response to chemotherapy, increasing from carcinoid 
to small-cell carcinoma. Ultrastructurally, the num- 
ber and size of the neurosecretory granules in small- 
cell carcinoma are smaller, as compared to carcinoid 
(1,4). Light microscopically, atypical carcinoid is 
distinguished from typical carcinoid by more numer- 
ous mitoses, cellular and nuclear polymorphism, 
hyperchromasia, a higher nucleus/cytoplasm ratio, 
more prominent nucleoli and the presence of necrosis 
(5). These characteristics are even more prominent in 
small-cell carcinoma (1,4,6). Immunocytochemical 
assay allows the demonstration of NSE, CEA, 
chromogranine A, synaptophysine, ACTH and other 
amines and peptides in the granules (16-8). As even 
the best marker, chromogranine A, is almost invari- 
ably present in carcinoid, but also in 20-50% of 
small-cell carcinomas, immunocytochemical assay is 
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Plate 4 Immunoreactivity for chromogranine A in neoplastic cells from an atypical carcinoid (PAP-method) (case 4). 
(nuclear stain: hematoxylin, 670 x ). - 
not very useful for differentiation within the neuro- 
endocrine tumour group (3,7). However, it is notable 
that the malignancy in these tumours is mainly a 
clinical feature, that does not completely correlate 
with the histologic aspect (9,lO). 
Differential diagnosis within the group of neuro- 
endocrine tumours is often difficult, especially on 
endoscopically obtained biopsies; more than half of 
the atypical carcinoids is diagnosed then as typical 
carcinoid or small-cell carcinoma (2,11-13). Simi- 
larly, in two of our patients, the initial diagnosis on 
biopsy was small-cell carcinoma. In the literature 
(13,14), more than 25% of resected ‘stage I small-cell 
carcinomas’, turned out to be atypical carcinoids. 
This illustrates the importance of resection of ‘stage I 
small-cell carcinomas’, as this therapy may be cura- 
tive if the tumour turns out to be atypical carcinoid. 
Bronchial carcinoid represents l-6% of all lung 
tumours, and 12% of all carcinoid tumours; only 
7.5-l 1.5% of bronchial carcinoids are atypical (4,9). 
The mean age of diagnosis of patients with typical 
carcinoid is 35-50, and with atypical carcinoid 55-60, 
but the range is wide (13-80 years) (2,5,10,14-16). 
The male/female ratio mentioned in literature differs 
widely (2/l to 0:6/l) (2,5,8,10,12,15,17-19). Typical 
carcinoid may be associated with the multiple endo- 
crine neoplasia (MEN) syndrome, but not with 
smoking habits or asbestos exposure (1,11,4). In 
contrast, 50% of atypical carcinoid patients and even 
more than 95% of small-cell carcinoma patients are 
smokers. When ‘small-cell carcinoma’ is presumably 
diagnosed in a non-smoker under the age of 45, a 
carcinoid tumour should actively be excluded 
(4,11,12,15). This is illustrated by our second case. 
Clinical manifestations depend on the site and 
the histologic type of the tumour: 80% of typical 
carcinoids are centrally located and cause slowly 
progressive bronchial obstruction with cough, fever, 
chest pain and local wheezing. Haemoptysis occurs in 
half of the cases, caused by the vascular nature of the 
tumour; atypical carcinoids rarely cause haemoptysis 
(4,9,10,11,18,20). Atypical carcinoids, which are 
often located peripherally, are frequently asymptom- 
atic. Symptoms can also result from metastases, for 
typical bronchial carcinoids metastasize in 2-20% of 
cases, mostly to liver and bone, sometimes to the 
heart, breast or eyes. Atypical carcinoids metastasize 
in 6&70% of patients, and in addition to liver and 
bone, also to the brain: they already express the 
neurotropism of small-cell carcinoma (2-5,12). In 
our patients, the only symptoms were cough and 
chest pain; three of the four tumours were located 
peripherally, and in both patients who developed 
metastases, these were in the brain. 
Carcinoid syndrome is seen in up to 13% of typical 
and atypical bronchial carcinoids, and in contrast 
with gastrointestinal carcinoid, the syndrome can 
be expressed without the presence of metastases. 
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None of our four patients expressed a carcinoid 
syndrome. 
There are no specific serologic tumour markers for 
carcinoid; NSE can be slightly elevated; in our 
patients it was normal 
On chest X-ray, centrally located tumours most 
often only show a retro-obstructive infiltrate or 
atelectasis. Peripheral tumours feature as a solitary 
nodule, sometimes lobulated, with a mean diameter 
of 4 cm, rare calcifications, and mostly located in the 
right upper lobe, the middle lobe or the lingula (2). 
The tumours are two to three times more frequent on 
the right side compared to the left side (10,18). 
Bronchoscopy shows, in centrally located tumours, 
a friable polypoid or a submucosal infiltrating lesion 
(11). 
Therapy of typical and localized atypical carcinoid 
is primarily surgical: conservative resection in suf- 
ficient in typical carcinoid; local recurrences nearly 
never develop. However, as in atypical carcinoid 
lymphatic involvement is frequent, a more radical 
resection, with lymph node dissection, is proposed 
(21). Postoperatively or in inoperable patients, an 
expectant attitude can be assumed if the patient 
is asymptomatic or if signs of aggressive tumour 
behaviour are lacking (9,ll). Sometimes, preoper- 
ative partial tumour resection with a Nd-YAG 
laser is feasible, resulting in lung tissue sparing 
surgery. 
Carcinoid tumours are much less sensitive to 
chemotherapy than small-cell carcinomas. 
5-Fluorouracil, streptozotocin, doxorubicine, cyclo- 
phosphamide, dacarbazine and methotrexate have all 
been tested alone or in combination therapy, with a 
response rate of maximally 3&40%, and considerable 
side effects. Rarely, good clinical response to treat- 
ment with small-cell lung carcinoma protocols (doxo- 
rubicin, cyclophosphamide, etoposide and cisplatin, 
in different combinations) is reported (22,23). Alpha- 
interferon has a response rate of 47%, and its 
complications are less severe (9). 
Radiotherapy can be used for brain metastases and 
symptomatic therapy of skin, liver and bone 
metastases (9). 
Typical carcinoid has a favourable prognosis: a 
global median 5-yr survival of 87%: 96% in stage I, 
71% in stages II and III, 11% in stage IV. Five-year 
survival of atypical carcinoid is 40-70%; that is why 
some authors suggest a more aggressive therapy 
(4,6,9,20,24). Prognosis is determined by histologic 
type, stage, operability and presence of symptoms 
(20,24). Considering the unfavourable prognosis of 
small-cell carcinoma, survival of more than 5 yr 
warrants revision of its diagnosis (4,14). 
In conclusion, we would like to stress the import- 
ance of an exact histologic diagnosis of neuroendo- 
crine bronchial carcinomas, as it considerably affects 
treatment and prognosis. Our patient series illustrates 
the therapeutic options and the diagnostic pitfalls. 
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